Herantis Pharma Plc

About Herantis Pharma Plc

Herantis Pharma is dedicated to developing innovative, disease-modifying therapies aimed at stopping or reversing the progression of neurodegenerative diseases to address unmet medical needs.

Products & Services

HER-096:A therapy under development, with details on its mechanism of action in the body provided on the website.

Pipeline and Clinical Trials:Various therapies in development for neurodegenerative diseases, with ongoing clinical trials and scientific publications.

Specialties

Disease-modifying therapies Neurodegenerative diseases Clinical trials Biomarker research

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Grant T: - FT: Grant	A: 8800000 MR: - FA: EUR 8.0 million FAN: 8800000	D: 2026-02-19 FD: 2026-02-19	1 investors

Grant Latest

2026-02-19

$8.8M

1 investor (Pro only)

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

A

Anders Gersel Pedersen

M.D., Chairman of the Scientific Advisory Board

A

Alberto Espay

M.D., MSc.

D

David Dexter

Associate Research Director of Parkinson's UK and Visiting Professor of Neuropharmacology at Imperial College London

D

Daniele Bravi

Associate Professor, M.D.

K

Kyösti Kakkonen

Chair

P

Petteri Vaarnanen

Member of Shareholders' Nomination Committee

View 12 more team members with Pro

Unlock Full Team Directory

Recent News